Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry

Table 2 Comparison of oral rapamycin vs drug eluting stent treatment in patients under 65 years old and equal to or older than 65 years old at 5.1 years (4.2-5.8) of follow-up

	< 65 yr			≥65 yr
	OR (n = 60)	DES (n = 52)	P value	OR (n = 40)	DES (n = 48)	P value
Death	3.3% (2)	9.6% (5)	0.32	7.5% (3)	20.8% (10)	0.07
Cardiac death	0.0% (0)	5.8% (3)	0.19	5.0% (2)	12.5% (6)	0.22
MI	10% (6)	13.5% (7)	0.56	0.0% (0)	12.5% (6)	0.05
Death + MI + CVA	10.0% (6)	13.5% (7)	0.56	7.5% (3)	25.0% (12)	0.03
TVF	26.7% (16)	28.8% (15)	0.79	22.5% (9)	45.8% (22)	0.02
TLR	9.3% (9/97)	14.6% (12/82)	0.26	11.5% (7/61)	20.5% (18/88)	0.14
TVR	14.8% (12/81)	17.4% (12/69)	0.66	14.0% (7/50)	21.9% (16/75)	0.26
New hospital admissions1	45.0% (27)	34.6% (18)	0.26	37.5% (15)	64.6% (31)	0.01
Continue clopidogrel therapy2	15.5% (9/58)	44.7% (21/47)	0.002	24.3% (9/37)	52.6% (20/38)	0.05

¹Patients with at least one cardiovascular or not cardiovascular hospital readmissions;

²Of surviving patients. OR: Oral rapamycin therapy and bare metal stent; DES: Drug eluting stent; MI: Myocardial Infarction; CVA: Cerebrovascular accident; TVF: Target vessel failure; TLR: Target lesion revascularization; TVR: Target vessel revascularization.